Arbour Group,
LLC is one of a small handful of US
firms specializing in offering regulatory
products and services to the
pharmaceutical,
medical device and
biotechnology industries. Regulatory
compliance is what ensures that poisonous or adulterated feedstock
do not enter into the manufacturing chain. Examples of what happens
when the system breaks down include several recent poisoning cases
where glycerine has been replaced with
diethelyne
glycol.
Arbour Group has an extensive practice in
FDA part
11<ref>http://www.fda.gov/ora/compliance_ref/part11/ :
FDA 21 CFR Part 11. Retrieved 6/20/2006</ref> compliance, a
major requirement that has to be fulfilled before they are
permitted to enter the US marketplace. The US electronic signature
requirements are considered the world's gold standard and thus
compliance with the US standard is also accepted by other major
regulators. Arbour Group engages in Part 11 certification efforts
world-wide with personnel on three continents.
Arbour Group's
innovative certification script products allow pharmaceutical and
medical device companies using a wide variety of computer systems
to quickly get their internal certification efforts up to speed,
allowing them to avoid reinventing the wheel. By offering both
custom and packaged solutions across a broad variety of platforms,
Arbour Group is unique in its field. In 1988, in combination with
Agile Software, Arbour Group was the first company to offer a
packaged software solution for FDA intended software
validation
[866].
Arbour Group's regulatory
services offer distinct benefits in:
evaluating regulatory
compliance identifying associated risk factors enhancing
productivity via reduction in application development and
implementation time capitalizing on the investment in software
systems improving quality policy and standard operating
procedures providing a qualified, third-party analysis of
automated systemsArbour Group's clients often outsource their
entire regulatory validation and testing process, making this
company a critical part of the chain from research lab to drugstore
shelf.
References
<references />